# Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

> **NCT05572970** · — · AVAILABLE · sponsor: **Agenus Inc.**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Balstilimab
- **DRUG:** Zalifrelimab

## Key facts

- **NCT ID:** NCT05572970
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05572970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05572970, "Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05572970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*